A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Memorial Sloan Kettering Cancer Center
Summary
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma. o Patients will be eligible regardless of the number of prior systemic therapies received. * Cohort 2: Must have a confirmed diagnosis of unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) that is refractory to at least 1 prior line of systemic therapy * Unresectable disease will be defined by an expert sarcoma surgical oncologist as either (a) low likelihood of obtaining an R0 resection or (b) unacceptable morbidity from a surgical pro…
Interventions
- BiologicalLifileucel (LN-144/LN-145)
Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
Locations (2)
- Memorial Sloan Kettering WestchesterHarrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York